Dabigatran etexilate (BIBR 1048) 是具有口服活性的 Dabigatran （一種凝血酶抑制劑）的前體。Dabigatran etexilate具有抗凝作用，可以預(yù)防心房顫動引起的靜脈血栓栓塞和中風(fēng)。

Dabigatran etexilate (BIBR 1048; oral; 10, 20 and 50 mg/kg for rats and 1, 2.5 and 5 mg/kg for monkeys) has dose- and time-dependent anticoagulant effects and has maximum effects between 30 and 120 min after administration, respectively[1].
Dabigatran etexilate maximally and significantly prolongs partial thromboplastin time (aPTT) to 25.2, 38.4 and 78.3 s in 30 min after 10, 20 and 50 mg/kg oral doses, respectively[1].
Dabigatran etexilate maximally prolongs the aPTT to 34.3 s, 44.0 s, and 63.0 s, respectively, 2h after 1, 2.5 or 5 mg/kg doses in the monkey[1].